Age (years) |
71.72 ± 11.18 |
61.85 ± 10.85 |
<0.001 |
Male/Female |
20/5 |
43/10 |
0.906 |
Month |
46.25 ± 51.92 |
57.06 ± 54.35 |
0.667 |
LVEF (%) |
32.67 ± 3.66 |
28.43 ± 5.92 |
0.002 |
NYHA Class II-III or IV |
2.92 ± 0.65 |
2.81 ± 0.62 |
0.859 |
Hypertension, n (%) |
22 (88.0) |
21 (39.6) |
<0.001 |
SBP (mmHg) |
124.52 ± 14.39 |
122.11 ± 17.99 |
0.560 |
DBP (mmHg) |
70.96 ± 9.68 |
77.55 ± 11.46 |
0.015 |
Diabetes, n (%) |
11 (44.0) |
11 (20.8) |
0.033 |
Atrial fibrillation, n (%) |
6 (24.0) |
12 (22.6) |
0.894 |
CAG, n (%) |
22 (88.0) |
20 (37.7) |
<0.001 |
CTA, n (%) |
0 (0.0) |
2 (3.8) |
0.159 |
BNP (Ng/L) |
908.50 ± 717.34 |
891.40 ± 733.72 |
0.929 |
Creatinine (mmol/L) |
93.86 ± 24.20 |
84.81 ± 30.39 |
- |
Medication |
|
|
|
Aspirin, n (%) |
16 (64.0) |
14 (26.4) |
0.122 |
P2Y12 Receptor Inhibitors, n (%) |
9 (36.0) |
1 (1.9) |
0.001 |
Statins, n (%) |
23 (92.0) |
16 (30.2) |
<0.001 |
Diuretics, n (%) |
21 (84.0) |
44 (83.0) |
0.915 |
Spironolactone, n (%) |
18 (72.0) |
41 (77.4) |
0.624 |
ACEI, n (%) |
14 (56.0) |
38 (71.7) |
0.194 |
ARB, n (%)) |
5 (20.0) |
6 (11.3) |
0.310 |
β-blocker, n (%) |
24 (96.0) |
47 (88.7) |
0.222 |
Anticoagulant,
n (%) |
4 (16.0) |
7 (13.2) |
0.745 |
Amiodarone,
n (%) |
2 (8.0) |
3 (5.7) |
0.717 |
Valsartan
Sodium Tablets, n (%) |
2 (8.0) |
1 (1.9) |
0.304 |
Trimetazidine Hydrochloride, n (%) |
8 (32.0) |
8 (15.1) |
0.124 |